


## Data Sheet

<b>Product Name:</b>	Ingliforib
<b>Cat. No.:</b>	CS-0015497
<b>CAS No.:</b>	186392-65-4
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>24</sub> CIN <sub>3</sub> O <sub>5</sub>
<b>Molecular Weight:</b>	457.91
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Solubility:</b>	DMSO : 130 mg/mL (283.90 mM; Need ultrasonic)



### BIOLOGICAL ACTIVITY:

Ingliforib is a **glycogen phosphorylase** inhibitor, with IC<sub>50</sub>s of 52, 352 and 150 nM for liver, muscle and brain glycogen phosphorylase, and has cardioprotective activity. IC<sub>50</sub> & Target: IC<sub>50</sub>: 52 nM (liver Glycogen phosphorylase), 352 nM (Muscle Glycogen phosphorylase), 150 nM (Brain Glycogen phosphorylase)<sup>[1]</sup> **In Vitro:** Ingliforib is a glycogen phosphorylase inhibitor, and inhibits the myocardial GP isoforms (muscle and brain) with IC<sub>50</sub>s of 352 and 150 nM, respectively, also a potent inhibitor of the liver isoform (IC<sub>50</sub> of 52 nM). Ingliforib (0.1, 1, 10 μM) dose-dependently reduces infarct size in the isolated rabbit hearts<sup>[1]</sup>. **In Vivo:** Ingliforib (15 mg/kg) potently reduces infarct size by 52%, and decreases plasma glucose and lactate concentrations in openchest anesthetized rabbits. Ingliforib (15 mg/kg) also inhibits myocardial glycogen phosphorylase a (GP<sub>a</sub>) and total glycogen phosphorylase (GP) activity in anesthetized rabbits<sup>[1]</sup>.

### PROTOCOL (Extracted from published papers and Only for reference)

#### Animal Administration: <sup>[1]</sup>Rabbits<sup>[1]</sup>

Male New Zealand White rabbits (3 to 4 kg) are used in the assay. At least 1 h after surgery, when arterial pressure, heart rate (HR), and rate-pressure product (RPP) have stabilized for at least 30 min (baseline), the rabbits receive a bolus of either 15.4 mg/kg of Ingliforib or vehicle (administered in 15 s), followed by a constant infusion of 23.1 mg/kg/h Ingliforib or vehicle at the same dose volume for a total of 3.5 h.

### References:

[1]. Tracey WR, et al. Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor. Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1177-84.

### CAIndexNames:

1H-Indole-2-carboxamide, 5-chloro-N-[(1S,2R)-3-[(3R,4S)-3,4-dihydroxy-1-pyrrolidinyl]-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-

### SMILES:

O=C(C(N1)=CC=C1C=CC(Cl)=C2)N[C@@H](CC3=CC=CC=C3)[C@@H](O)C(N4C[C@@H](O)[C@@H](O)C4)=O

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA